NEET PG biochemistry questions

ALA synthase (ALAS) catalyzes the first and rate-limiting step of heme synthesis, condensing glycine and succinyl-CoA in a reaction requiring pyridoxal phosphate. Heme, the end product, represses ALAS gene transcription and inhibits its transport into mitochondria, forming a classic negative feedback loop. Drugs that induce cytochrome P450 (such as many anticonvulsants) deplete the free heme pool, derepressing ALAS and precipitating acute attacks in susceptible individuals with porphyria. This mechanism explains drug-precipitated acute intermittent porphyria.

• B. This enzyme acts later in the cytoplasmic pathway and is not feedback-regulated by heme.
• C. This enzyme is deficient, not regulatory, in acute intermittent porphyria and is not the rate-limiting or feedback-regulated step.
• D. Ferrochelatase catalyzes the final step, inserting iron into protoporphyrin IX, and is not the rate-limiting enzyme.

Serum lipase is more specific for pancreatic injury than amylase because lipase is produced almost exclusively by the pancreas, whereas amylase is also secreted by the salivary glands and can be elevated in parotitis, macroamylasemia, and other conditions. Lipase also rises earlier and remains elevated longer than amylase in acute pancreatitis, improving diagnostic sensitivity. Current guidelines recommend lipase, or amylase plus lipase together, over amylase alone for diagnosing acute pancreatitis. A lipase level more than three times the upper limit of normal strongly supports the diagnosis.

• A. ALT reflects hepatocellular injury and is used to suggest a biliary cause of pancreatitis, not to confirm pancreatic origin of hyperamylasemia.
• C. GGT is a marker of hepatobiliary disease and alcohol use, not specific for pancreatitis.
• D. Alkaline phosphatase reflects biliary obstruction or bone turnover, not pancreatic acinar injury specifically.

LDH1 (H4), composed predominantly of heart-type subunits, normally runs lower than LDH2 (H3M1) in healthy serum, giving an LDH2 greater than LDH1 pattern. In myocardial infarction, myocardial cell necrosis releases large amounts of LDH1, reversing the normal ratio so that LDH1 exceeds LDH2, a pattern called "flipped LDH." This flip typically appears by 12-24 hours and can persist up to 7-10 days, making it useful for late presentations when troponin has normalized. Liver and skeletal muscle injury instead raise LDH5, the M4 isoenzyme.

• A. Hemolysis releases LDH1 and LDH2 from red cells but does not by itself reverse the LDH1:LDH2 ratio to the degree seen with myocardial necrosis.
• B. Skeletal muscle injury raises LDH5, not LDH1, since skeletal muscle is rich in M subunits.
• C. Hepatocellular necrosis predominantly elevates LDH5 (muscle-type, M4 subunit), not LDH1.

Alpha-ketoglutarate dehydrogenase requires thiamine pyrophosphate as an essential cofactor to catalyze the oxidative decarboxylation of alpha-ketoglutarate to succinyl-CoA in the citric acid cycle. In thiamine deficiency, reduced activity of this enzyme impairs mitochondrial ATP generation, and neurons in highly oxidative, thiamine-dependent regions such as the mammillary bodies and periaqueductal gray are especially vulnerable, producing the ophthalmoplegia, ataxia and confusion of Wernicke encephalopathy. Pyruvate dehydrogenase is also thiamine-dependent but is not a Krebs cycle enzyme itself. Prompt thiamine replacement reverses the enzymatic block and can reverse early symptoms.

• A. Succinate dehydrogenase uses FAD, not thiamine pyrophosphate, as its cofactor.
• B. Isocitrate dehydrogenase uses NAD+ as a cofactor and does not require thiamine pyrophosphate.
• D. Citrate synthase does not require thiamine pyrophosphate and does not catalyze an oxidative decarboxylation.

Wet beriberi is the cardiovascular form of thiamine deficiency, characterized by high-output heart failure with peripheral edema, tachycardia, and a wide pulse pressure due to peripheral vasodilation from impaired oxidative metabolism and compensatory arteriovenous shunting. Dry beriberi instead predominantly affects the peripheral nerves, producing symmetric sensorimotor polyneuropathy without significant cardiac involvement. The polished rice diet is a classic risk factor since thiamine is concentrated in the rice husk, which is removed during polishing. Distinguishing wet from dry beriberi guides clinical suspicion, though both respond to thiamine repletion.

• A. Pellagra is caused by niacin deficiency and presents with dermatitis, diarrhea and dementia, not high-output heart failure.
• C. Subacute combined degeneration results from vitamin B12 deficiency and affects the dorsal columns and corticospinal tracts, not the cardiovascular system.
• D. Dry beriberi presents with peripheral neuropathy rather than high-output cardiac failure and edema.

Riboflavin deficiency classically causes angular stomatitis (cracks at the mouth corners), magenta glossitis, and seborrheic dermatitis affecting the nasolabial folds, scrotum or vulva. Riboflavin is a precursor of the coenzymes FAD and FMN, which are essential for numerous oxidation-reduction reactions, and deficiency impairs mucosal and epithelial cell turnover, producing these characteristic mucocutaneous findings. Dietary sources include milk, eggs, and leafy green vegetables, and deficiency is more common in populations with limited intake of these foods. Treatment is oral riboflavin supplementation with dietary correction.

• A. Niacin deficiency causes pellagra with dermatitis, diarrhea and dementia, not the characteristic magenta tongue and angular stomatitis of riboflavin deficiency.
• B. Pyridoxine deficiency causes peripheral neuropathy, seizures and sideroblastic anemia rather than this mucocutaneous pattern.
• D. Folate deficiency causes megaloblastic anemia and neural tube defects, not angular stomatitis and magenta glossitis.

Pellagra results from niacin deficiency and classically presents with the triad of dermatitis, diarrhea and dementia. Maize is deficient in both niacin and the essential amino acid tryptophan, which is normally a minor endogenous source of niacin through a pathway requiring vitamin B6-dependent enzymes; maize protein (zein) is also poor in tryptophan, compounding the deficiency. Niacin is required to synthesize NAD+ and NADP+, coenzymes central to oxidative energy metabolism, and their deficiency impairs energy-dependent processes in rapidly dividing epithelium, gut mucosa and neurons, producing the classic triad. Treatment with niacin or a tryptophan-rich, balanced protein diet reverses the clinical features.

• A. This pathway relates to cystathionine metabolism and homocystinuria, not pellagra.
• C. This pathway relates to phenylketonuria and catecholamine synthesis, unrelated to the pellagra triad.
• D. This pathway is unrelated to niacin metabolism or the pellagra triad.

Isoniazid forms a hydrazone complex with pyridoxal phosphate and also inhibits the enzyme pyridoxine kinase, which is required to convert pyridoxine to its active cofactor form, pyridoxal phosphate. Pyridoxal phosphate is an essential cofactor for transaminases, glutamate decarboxylase (synthesizing GABA), and delta-aminolevulinic acid synthase in heme synthesis, so its depletion impairs neurotransmitter synthesis and nerve function, producing a symmetric peripheral neuropathy. This adverse effect is preventable with prophylactic pyridoxine supplementation, routinely co-administered with isoniazid in at-risk patients such as pregnant women, malnourished individuals, and those with diabetes or HIV. Isoniazid-induced neuropathy is a key dose-related adverse effect taught alongside isoniazid-induced hepatotoxicity.

• A. Cobalamin deficiency causes subacute combined degeneration and megaloblastic anemia, unrelated to isoniazid metabolism.
• C. Thiamine deficiency is not caused by isoniazid and classically presents with beriberi or Wernicke encephalopathy rather than this specific drug-induced neuropathy.
• D. Folate deficiency causes megaloblastic anemia, not the peripheral neuropathy characteristic of isoniazid therapy.

Phosphofructokinase-1 (PFK-1) catalyzes the conversion of fructose-6-phosphate to fructose-1,6-bisphosphate and is the key rate-limiting, irreversible, and most tightly regulated step of glycolysis. It is allosterically inhibited by high ATP and citrate (signaling adequate energy and citric acid cycle intermediates) and activated by AMP (signaling low energy) and fructose-2,6-bisphosphate (the key signal for fed-state glycolysis generated by phosphofructokinase-2 in response to insulin). Hexokinase and pyruvate kinase are also regulated but are not the primary rate-limiting step of the pathway.

• A. Pyruvate kinase catalyzes the final step and is regulated by fructose-1,6-bisphosphate and ATP, but it is not the primary control point described here.
• B. Hexokinase catalyzes the first committed step of glucose metabolism and is inhibited by its product glucose-6-phosphate, but it is not the rate-limiting enzyme of glycolysis itself.
• C. Aldolase catalyzes a reversible cleavage step and is not allosterically regulated by ATP, citrate, AMP, or fructose-2,6-bisphosphate.

Von Gierke disease (GSD type I) is caused by deficiency of glucose-6-phosphatase, the enzyme that catalyzes the final step of both glycogenolysis and gluconeogenesis by converting glucose-6-phosphate to free glucose. Loss of this step causes severe fasting hypoglycemia unresponsive to glucagon, along with accumulation of glucose-6-phosphate that is shunted into glycolysis (lactic acidosis), the pentose phosphate pathway (hyperuricemia from increased purine degradation), and lipogenesis (hypertriglyceridemia). The massive hepatomegaly results from glycogen and fat accumulation in hepatocytes, and the doll-like facies with thin limbs and truncal fat is a classic described phenotype. Management includes frequent feeds and uncooked cornstarch to prevent hypoglycemia.

• A. Muscle phosphorylase deficiency (McArdle disease, GSD V) causes exercise intolerance without fasting hypoglycemia, since it does not affect hepatic glucose output.
• B. Debranching enzyme deficiency (GSD III, Cori disease) causes milder hypoglycemia with normal or mildly elevated lactate and responds partially to glucagon after a short fast.
• D. Fructose-1,6-bisphosphatase deficiency impairs gluconeogenesis only, sparing glycogenolysis, so hypoglycemia is typically precipitated by fasting or illness rather than being this severe and glycogen-storage-predominant.

McArdle disease (GSD type V) results from deficiency of myophosphorylase, the muscle-specific isoform of glycogen phosphorylase, which prevents glycogenolysis in skeletal muscle during anaerobic, high-intensity exercise. This causes early muscle fatigue, cramps, and myoglobinuria due to rhabdomyolysis, with a resting elevated CK reflecting chronic muscle membrane leakage. The 'second wind' phenomenon occurs because, after brief rest, increased blood flow delivers free fatty acids and glucose from the circulation that can be used aerobically, bypassing the defective glycogenolytic pathway. Liver glycogen metabolism and blood glucose maintenance are unaffected, so fasting hypoglycemia does not occur.

• A. Acid alpha-glucosidase deficiency (Pompe disease) causes a lysosomal storage myopathy with progressive weakness and cardiomegaly in infancy, not isolated exercise-induced cramping with a second-wind phenomenon.
• B. Carnitine palmitoyltransferase II deficiency impairs long-chain fatty acid oxidation and classically causes myalgia with prolonged, low-intensity exercise or fasting, not the second-wind phenomenon seen with glycogenolytic defects.
• C. Hepatic glucose-6-phosphatase deficiency causes fasting hypoglycemia (Von Gierke disease), not exercise-induced muscle cramps with a normal fasting glucose.

Pompe disease (GSD type II) is caused by deficiency of lysosomal acid alpha-glucosidase (acid maltase), the enzyme responsible for degrading glycogen that has been taken up into lysosomes by autophagy. Because the defect is lysosomal rather than cytoplasmic, glycogen accumulates within lysosomes throughout the body, producing a distinctive vacuolar, diastase-resistant PAS-positive pattern on biopsy. The infantile form presents with severe hypotonia, macroglossia, and massive cardiomegaly leading to early heart failure and death if untreated, distinguishing it from other GSDs that mainly affect liver or muscle cytoplasmic glycogen metabolism. Enzyme replacement therapy with recombinant alglucosidase alfa is the mainstay of treatment.

• A. Branching enzyme deficiency causes GSD type IV (Andersen disease), characterized by progressive liver cirrhosis, not a lysosomal storage pattern with cardiomegaly.
• C. Liver phosphorylase deficiency causes GSD type VI, a mild hepatic glycogenosis with hepatomegaly and mild hypoglycemia, without lysosomal storage or cardiomegaly.
• D. Phosphoglucomutase deficiency is an extremely rare cause of glycogen storage disease affecting glycolysis/glycogenolysis interconversion, not a lysosomal enzyme defect.

Classic galactosemia is caused by deficiency of galactose-1-phosphate uridyltransferase (GALT), which leads to accumulation of galactose-1-phosphate in the liver, kidney, brain, and lens. This causes hepatomegaly, jaundice, cataracts, vomiting, failure to thrive, and a predisposition to E. coli sepsis, classically attributed to impaired neutrophil function and the favorable growth of E. coli in a galactose-rich environment. The urine reducing substance test is positive (galactose reduces copper sulfate) while the glucose-specific oxidase test is negative, confirming a non-glucose reducing sugar. Because galactosemia is a treatable cause of neonatal illness and blindness, it is included in many newborn screening programs, with treatment being lifelong exclusion of galactose and lactose from the diet.

• A. UDP-galactose-4-epimerase deficiency is usually a rare, often clinically mild or peripheral form of galactosemia and is not the classic severe presentation described here.
• B. Aldose reductase catalyzes glucose to sorbitol conversion in the polyol pathway and is unrelated to galactose metabolism or this clinical picture.
• C. Galactokinase deficiency causes isolated cataracts without hepatomegaly, sepsis risk, or significant systemic toxicity, since galactose-1-phosphate does not accumulate.

Hereditary fructose intolerance is caused by deficiency of aldolase B, the liver enzyme that cleaves fructose-1-phosphate in the second step of fructose metabolism. Fructose-1-phosphate accumulates after ingestion of fructose or sucrose (which is hydrolyzed to fructose and glucose), trapping hepatic phosphate and causing severe hypoglycemia, hypophosphatemia, and inhibition of both glycogenolysis and gluconeogenesis. Symptoms classically appear when fructose-containing foods such as fruit juices or sweetened weaning foods are introduced, as seen in this previously asymptomatic breastfed infant. Chronic exposure leads to vomiting, failure to thrive, hepatomegaly, and renal tubular dysfunction, and management requires strict dietary exclusion of fructose, sucrose, and sorbitol.

• A. Fructokinase deficiency (essential fructosuria) is a benign, asymptomatic condition with fructose appearing in urine but no toxic metabolite accumulation.
• C. Sucrase-isomaltase deficiency causes carbohydrate malabsorption with osmotic diarrhea after sucrose ingestion, not hypoglycemia or hypophosphatemia.
• D. Fructose-1,6-bisphosphatase deficiency impairs gluconeogenesis and causes fasting hypoglycemia with lactic acidosis, but it is not specifically triggered by fructose/sucrose ingestion in the same way and does not cause marked hypophosphatemia from fructose-1-phosphate trapping.

HbA1c reflects the average blood glucose concentration over the preceding 8-12 weeks because glucose binds irreversibly and non-enzymatically to hemoglobin over the lifespan of the red blood cell, roughly 120 days. In conditions with increased red cell turnover, such as hemolytic anemias (e.g., hereditary spherocytosis) or after blood transfusion, red cells are destroyed and replaced prematurely, so there is less time for glycation to occur, leading to a falsely low HbA1c despite poor actual glycemic control. This is a well-recognized limitation of HbA1c, and in such patients fructosamine (reflecting glycation of serum proteins over 2-3 weeks) or direct glucose monitoring is preferred for assessing control. Clinicians must recognize this discordance to avoid under-treating hyperglycemia.

• A. Oxygen affinity of transfused hemoglobin is unrelated to the measurement or interpretation of glycated hemoglobin levels.
• C. Glycated hemoglobin is not renally cleared; it is removed from circulation only when the red cell itself is destroyed.
• D. Metformin acts mainly by reducing hepatic gluconeogenesis and improving insulin sensitivity; it does not inhibit hemoglobin glycation chemistry.

Familial hypercholesterolemia is an autosomal dominant disorder most commonly caused by mutations in the gene encoding the LDL receptor, which impair hepatic uptake and clearance of circulating LDL particles. This leads to markedly elevated LDL cholesterol from birth, with heterozygotes typically showing total cholesterol in the 300-500 mg/dL range and homozygotes showing even higher levels with onset of disease in childhood. The clinical hallmarks are tendon xanthomas (classically Achilles and extensor tendons of the hand), corneal arcus, and premature coronary artery disease, often with a strong family history of early myocardial infarction. Diagnosis is clinical and supported by lipid profile and family history, with statins being first-line therapy, and PCSK9 inhibitors or LDL apheresis reserved for severe or homozygous cases.

• A. Apolipoprotein C-II deficiency similarly causes a chylomicronemia syndrome with severe hypertriglyceridemia, not the isolated hypercholesterolemia pattern seen here.
• B. Apolipoprotein B-48 defects affect chylomicron formation and cause abetalipoproteinemia-related fat malabsorption, not elevated LDL cholesterol with tendon xanthomas.
• D. Lipoprotein lipase deficiency causes type I hyperlipoproteinemia with massive chylomicronemia, severe hypertriglyceridemia, and eruptive xanthomas, not isolated high LDL with tendon xanthomas.

Statins competitively inhibit HMG-CoA reductase, the rate-limiting enzyme of hepatic cholesterol synthesis, which upregulates LDL receptor expression and lowers plasma LDL-cholesterol. This same class is the most common cause of drug-induced myopathy, ranging from myalgia to rhabdomyolysis, due to reduced synthesis of isoprenoid intermediates needed for normal muscle cell function. Risk is increased with higher doses, hypothyroidism, renal impairment, and concomitant fibrates or CYP3A4 inhibitors. Markedly elevated CK with myalgia in a patient on this therapy is a classic presentation of statin-induced myopathy.

• A. This describes bile acid sequestrants (e.g., cholestyramine), which are not associated with myopathy.
• B. This describes fibrates, which can cause myopathy but act through PPAR-alpha, not HMG-CoA reductase inhibition.
• C. This describes ezetimibe, which does not cause myopathy of this severity.

Type I hyperlipoproteinemia (familial chylomicronemia) results from lipoprotein lipase deficiency or deficiency of its cofactor ApoC-II, causing massive accumulation of chylomicrons in plasma. This produces markedly elevated triglycerides with a creamy chylomicron layer on top and a clear infranatant on refrigeration, along with eruptive xanthomas and recurrent pancreatitis-like abdominal pain in childhood. Total cholesterol is only mildly raised because chylomicrons carry mostly triglyceride. This pattern is distinct from the isolated LDL elevation of Type IIa or the mixed patterns of Type III and IV. This is a mechanism-based explanation correlating lipoprotein biochemistry with clinical and gross plasma findings.

• A. Type IIa shows isolated LDL elevation with a clear plasma sample, not chylomicronemia.
• B. Type IV shows elevated VLDL with turbid but not creamy plasma and normal lipoprotein lipase activity.
• C. Type III (dysbetalipoproteinemia) shows broad beta band on electrophoresis with palmar xanthomas, not a creamy chylomicron layer.

Carnitine is required to shuttle long-chain fatty acyl groups across the inner mitochondrial membrane via the carnitine-acylcarnitine translocase system (carnitine palmitoyltransferase I and II). Deficiency of carnitine or of CPT enzymes blocks beta-oxidation of long-chain fatty acids, so during fasting the liver cannot generate acetyl-CoA for ketogenesis, producing hypoketotic hypoglycemia despite high circulating free fatty acids. This is confirmed by low free carnitine with accumulation of long-chain acylcarnitines upstream of the block. Hepatomegaly results from fat accumulation in hepatocytes.

• A. Malonyl-CoA decarboxylase deficiency is a rare distinct disorder affecting malonyl-CoA metabolism, not the primary carnitine shuttle defect described.
• B. Acetyl-CoA carboxylase deficiency would not explain the specific acylcarnitine accumulation pattern seen in this infant.
• D. Reduced hormone-sensitive lipase would decrease free fatty acid release, not cause the elevated free fatty acids seen here.

Insulin deficiency and glucagon excess activate hormone-sensitive lipase, releasing free fatty acids that reach the liver in large amounts. Low insulin also lowers malonyl-CoA (via reduced acetyl-CoA carboxylase activity), relieving inhibition of carnitine palmitoyltransferase I, which allows unrestricted entry of fatty acyl-CoA into mitochondria for beta-oxidation. The resulting surge of acetyl-CoA exceeds the oxidative capacity of the TCA cycle and is diverted to ketone body synthesis (acetoacetate and beta-hydroxybutyrate), producing the anion-gap metabolic acidosis seen in diabetic ketoacidosis. This mechanism explains why ketogenesis, not glycogenolysis or gluconeogenesis directly, drives the acidosis.

• A. Glycogenolysis contributes to hyperglycemia but does not directly drive ketone body formation.
• C. Glycogen synthase activity is suppressed, not increased, in insulin deficiency and is unrelated to ketogenesis.
• D. Increased pyruvate carboxylase activity supports gluconeogenesis and worsens hyperglycemia but is not the direct cause of ketogenesis.

ApoC-II is a small apolipoprotein found on chylomicrons and VLDL that serves as the obligatory activating cofactor for lipoprotein lipase, the endothelial enzyme that hydrolyzes triglycerides into free fatty acids and glycerol for tissue uptake. Deficiency of ApoC-II or lipoprotein lipase itself causes severe hypertriglyceridemia (Type I hyperlipoproteinemia) despite normal enzyme protein being present. In contrast, ApoB-100 is the structural ligand for the LDL receptor, ApoA-I activates lecithin-cholesterol acyltransferase (LCAT) in HDL metabolism, and ApoE mediates receptor-mediated clearance of chylomicron and VLDL remnants.

• B. ApoA-I is the major HDL apolipoprotein that activates LCAT for cholesterol esterification, not lipoprotein lipase.
• C. ApoB-100 is the structural apolipoprotein of LDL that binds the LDL receptor, not the lipoprotein lipase activator.
• D. ApoE mediates hepatic uptake of chylomicron and VLDL remnants via the LDL receptor and LRP, not lipoprotein lipase activation.

Gaucher disease is caused by deficiency of glucocerebrosidase (acid beta-glucosidase), the lysosomal enzyme that cleaves glucocerebroside into glucose and ceramide. Glucocerebroside accumulates in macrophages, producing characteristic Gaucher cells with a crumpled-tissue-paper cytoplasmic appearance, seen in bone marrow, spleen, and liver. Clinical features include massive hepatosplenomegaly, bone pain with Erlenmeyer flask deformity of the femur, pathologic fractures, and pancytopenia from marrow infiltration and hypersplenism. Type 1 (non-neuronopathic) is the most common form and is treatable with enzyme replacement therapy (imiglucerase).

• A. Acid sphingomyelinase deficiency causes Niemann-Pick disease, with foam cells showing a zebra body pattern rather than crumpled-tissue-paper cytoplasm.
• B. Alpha-galactosidase A deficiency causes Fabry disease, presenting with angiokeratomas and neuropathic pain, not Gaucher cells.
• D. Hexosaminidase A deficiency causes Tay-Sachs disease, a neurodegenerative disorder with a cherry-red spot and no hepatosplenomegaly.

Phenylketonuria results from deficiency of phenylalanine hydroxylase, which normally converts phenylalanine to tyrosine in the liver using tetrahydrobiopterin as a cofactor. Loss of this enzyme causes accumulation of phenylalanine and its toxic metabolites (phenylpyruvate, phenylacetate), which impair myelination and brain development. Since tyrosine synthesis from phenylalanine is blocked, tyrosine becomes a conditionally essential amino acid that must be supplied in the diet. Management is a low-phenylalanine diet with tyrosine supplementation, started as early as possible and continued lifelong.

• A. Tryptophan metabolism is unrelated to the phenylalanine hydroxylase defect.
• B. Tyrosine is the product, not the toxic substrate; it must be supplemented, not restricted.
• D. Methionine/cysteine metabolism is affected in homocystinuria, not PKU.

Maple syrup urine disease is caused by deficiency of the branched-chain alpha-ketoacid dehydrogenase complex, a mitochondrial enzyme requiring thiamine pyrophosphate that normally decarboxylates the ketoacids derived from leucine, isoleucine, and valine. Its deficiency leads to accumulation of these three branched-chain amino acids and their ketoacids in blood and urine, producing the characteristic sweet, maple syrup-like odor. Untreated infants develop poor feeding, vomiting, lethargy, and encephalopathy within the first week of life. Diagnosis is confirmed by elevated plasma branched-chain amino acids and urinary ketoacids, and management involves dietary restriction of these amino acids.

• B. This causes a fatty acid oxidation defect presenting with hypoketotic hypoglycemia, unrelated to branched-chain amino acids.
• C. This causes methylmalonic acidemia, a different organic acidemia without the characteristic odor.
• D. Deficiency of this enzyme causes propionic acidemia, presenting with metabolic acidosis, not a sweet urine odor.

Alkaptonuria is an autosomal recessive disorder caused by deficiency of homogentisate 1,2-dioxygenase, an enzyme in the tyrosine degradation pathway that normally converts homogentisic acid to maleylacetoacetate. Accumulated homogentisic acid is excreted in urine, where it oxidizes and polymerizes on exposure to air, turning the urine black on standing. Chronic deposition of oxidized homogentisate pigment in connective tissue produces ochronosis, seen as bluish-black pigmentation of cartilage, sclera, and skin, along with premature degenerative arthropathy of large joints. Diagnosis is confirmed by detecting homogentisic acid in urine.

• B. Tyrosinase deficiency causes albinism due to absent melanin synthesis, not black urine.
• C. This enzyme deficiency causes tyrosinemia type I, presenting with liver failure and renal tubular dysfunction, not ochronosis.
• D. Deficiency of this enzyme causes tyrosinemia type III, not the black urine and ochronosis of alkaptonuria.

Classic homocystinuria is most commonly caused by cystathionine beta-synthase deficiency, a pyridoxal phosphate-dependent enzyme that converts homocysteine to cystathionine. Its deficiency causes accumulation of homocysteine and methionine, producing the clinical triad of marfanoid habitus, downward lens dislocation (ectopia lentis), and thromboembolic events. Elevated homocysteine damages vascular endothelium and promotes a prothrombotic state by increasing tissue factor expression and impairing nitric oxide-mediated vasodilation, predisposing to arterial and venous thrombosis including stroke. Management includes pyridoxine, folate, and vitamin B12 supplementation along with dietary methionine restriction.

• A. This causes methylmalonic acidemia, not the ectopia lentis and marfanoid habitus seen here.
• C. Methionine synthase deficiency causes homocystinuria with low, not elevated, methionine levels.
• D. Cystathionase deficiency causes cystathioninuria, a benign condition without thrombotic risk.

In the brain, astrocytes lack a complete urea cycle and instead detoxify ammonia primarily through glutamine synthetase, which combines ammonia with glutamate to form glutamine. In hepatic failure, chronically elevated ammonia drives excessive glutamine synthesis, and the resulting osmotic accumulation of glutamine within astrocytes causes cellular swelling, a key contributor to low-grade cerebral edema in hepatic encephalopathy. Glutamine also acts as a Trojan horse, being transported into mitochondria where it is hydrolyzed back to ammonia, perpetuating mitochondrial dysfunction and oxidative stress. This mechanism explains the correlation between hyperammonemia and the neuropsychiatric manifestations of hepatic encephalopathy.

• B. Alpha-ketoglutarate is consumed, not formed, in the glutamate dehydrogenase reaction that generates glutamate for ammonia fixation.
• C. GABA is an inhibitory neurotransmitter whose activity is altered in hepatic encephalopathy but is not the direct ammonia-detoxifying product.
• D. Glutathione is an antioxidant tripeptide unrelated to ammonia detoxification in astrocytes.

Oculocutaneous albinism type 1, the most common and severe form, results from deficiency or absence of tyrosinase, the rate-limiting enzyme that converts tyrosine to dopaquinone in the melanin synthesis pathway within melanocytes. Melanocytes are present in normal numbers but cannot synthesize melanin, resulting in generalized hypopigmentation of skin, hair, and eyes. Ocular findings include photophobia, nystagmus, reduced visual acuity, and a hypopigmented fundus due to lack of melanin in the retinal pigment epithelium and iris. The clinical spectrum ranges from complete absence of pigment (tyrosinase-negative) to partial pigment production (tyrosinase-positive), depending on residual enzyme activity.

• B. Dopa decarboxylase is involved in catecholamine synthesis, not the primary defect in albinism.
• C. This enzyme deficiency causes alkaptonuria, unrelated to pigmentation.
• D. Phenylalanine hydroxylase deficiency causes phenylketonuria, which can cause mild hypopigmentation but not the classic albinism phenotype described.

Acute intermittent porphyria is caused by a partial deficiency of porphobilinogen deaminase (hydroxymethylbilane synthase), the third enzyme of the heme synthesis pathway. Drugs like phenytoin that induce hepatic cytochrome P450 enzymes increase the demand for heme, which upregulates ALA synthase, the rate-limiting enzyme of the pathway, through loss of heme-mediated negative feedback. This drives further accumulation of the neurotoxic precursors ALA and porphobilinogen proximal to the partial enzyme block, precipitating an acute attack with abdominal pain, autonomic instability, and neuropsychiatric symptoms. Classic precipitants include barbiturates, phenytoin, sulfonamides, alcohol, and starvation, and management includes intravenous hemin and glucose to suppress ALA synthase induction.

• A. Uroporphyrinogen decarboxylase (uroporphyrinogen decarboxylase/cosynthase) deficiency causes porphyria cutanea tarda with skin photosensitivity, not acute neurovisceral attacks.
• B. ALA dehydratase deficiency porphyria is extremely rare, and phenytoin acts by inducing ALA synthase, not by directly inhibiting an enzyme.
• C. Ferrochelatase deficiency causes erythropoietic protoporphyria, characterized by painful photosensitivity, not acute abdominal attacks.

Lead has a high affinity for sulfhydryl groups and inhibits two key enzymes of heme synthesis: ALA dehydratase (most sensitive) and ferrochelatase. Inhibition of ALA dehydratase causes accumulation of delta-aminolevulinic acid (ALA) in blood and urine, a hallmark biochemical finding in lead poisoning. Ferrochelatase inhibition causes accumulation of protoporphyrin IX, which combines with zinc to give elevated zinc protoporphyrin, another diagnostic marker. Basophilic stippling results from residual ribosomal RNA aggregates due to disrupted RNA degradation.

• A. Not the principal target of lead; its deficiency causes hereditary coproporphyria.
• C. Not significantly affected by lead; its deficiency causes porphyria cutanea tarda.
• D. Not the primary enzyme inhibited by lead; it is inhibited by acute intermittent porphyria mutations, not lead toxicity.

Porphyria cutanea tarda is caused by deficiency of uroporphyrinogen decarboxylase (uroporphyrinogen III decarboxylase), leading to accumulation of uroporphyrin, which is photosensitizing and causes blistering skin lesions on sun-exposed areas. It is the most common porphyria and is often precipitated or unmasked by alcohol, estrogen use, hepatitis C, or iron overload. Unlike the acute porphyrias, there is no significant abdominal pain or neuropsychiatric involvement because porphobilinogen and ALA levels are not markedly elevated. Urine darkens on exposure to light and air due to oxidation of porphyrins.

• A. Ferrochelatase deficiency causes erythropoietic protoporphyria, presenting with acute painful photosensitivity without blistering, typically in childhood.
• C. Deficiency causes acute intermittent porphyria, which presents with abdominal pain and neuropsychiatric symptoms but no photosensitivity.
• D. ALA synthase is upregulated, not deficient, in porphyrias; its deficiency causes a rare sideroblastic anemia, not porphyria.

Sickle cell disease results from a single point mutation (GAG to GTG) in the sixth codon of the beta-globin gene, substituting hydrophobic valine for glutamate at position 6. This creates a hydrophobic patch on the surface of deoxygenated HbS that fits into a complementary hydrophobic pocket on an adjacent deoxy-HbS molecule, promoting polymerization into long fibers that distort the red cell into a sickle shape. Sickling is reversible with reoxygenation initially but repeated cycles cause irreversible membrane damage and hemolysis. This leads to vaso-occlusion, pain crises, and chronic hemolytic anemia.

• B. HbS has normal or slightly decreased oxygen affinity; the pathology arises from polymerization on deoxygenation, not from increased oxygen affinity.
• C. This describes the mechanism of beta-thalassemia, not sickle cell disease.
• D. This describes a mechanism seen in some unstable hemoglobin variants, not HbS, which results from a missense mutation.

In beta-thalassemia trait, one beta-globin allele has reduced output, decreasing beta-chain synthesis. Free alpha chains, which are produced in relative excess, then pair preferentially with the available delta chains to form more HbA2 (alpha2-delta2) and, to a lesser extent, with gamma chains to form HbF. This compensatory shift results in the characteristic elevated HbA2 (greater than 3.5%) seen in beta-thalassemia trait, a key diagnostic marker that distinguishes it from iron deficiency anemia, which also causes microcytosis but with normal or low HbA2.

• A. Increased HbF synthesis does occur mildly but does not explain the specific rise in HbA2, which is the diagnostic hallmark.
• C. Iron metabolism is unrelated to delta-chain globin gene expression or HbA2 levels.
• D. Alpha-thalassemia reduces alpha-chain production and does not raise HbA2; it may even lower it.

Conjugated bilirubin is water-soluble (unlike unconjugated bilirubin, which is bound to albumin and lipid-soluble) and can be filtered by the glomerulus and excreted in urine, producing bilirubinuria, a feature only of conjugated hyperbilirubinemia. Reduced bile flow into the intestine, due to hepatocellular or obstructive pathology, decreases the amount of bilirubin converted by gut bacteria into urobilinogen, which normally gets partly reabsorbed and excreted in urine; hence urine urobilinogen is low or absent. This pattern, with predominantly conjugated hyperbilirubinemia, bilirubinuria, and absent urobilinogen, points toward a hepatocellular or obstructive cause rather than hemolysis.

• A. This describes hemolytic (unconjugated) hyperbilirubinemia, which does not cause bilirubinuria since unconjugated bilirubin is not filtered by the kidney.
• B. Unconjugated bilirubin is not water-soluble and is never excreted in urine regardless of its serum level.
• D. Urobilinogen is formed by gut bacterial action on bilirubin in the intestine, not within the renal tubule.

Crigler-Najjar syndrome type 1 results from complete absence of UDP-glucuronosyltransferase (UGT1A1) activity, causing severe unconjugated hyperbilirubinemia that can lead to kernicterus (manifesting as lethargy and opisthotonus) if untreated. Gilbert syndrome, in contrast, is a much milder condition with 20-30% residual UGT1A1 activity, causing mild unconjugated hyperbilirubinemia usually under 3 mg/dL that becomes apparent during stress, fasting, or illness, without neurological complications. Crigler-Najjar type 2 has partial enzyme deficiency and responds to phenobarbital, unlike type 1, which requires phototherapy and often liver transplantation.

• A. Dubin-Johnson syndrome causes conjugated hyperbilirubinemia due to a canalicular transport defect, not unconjugated hyperbilirubinemia.
• C. Gilbert syndrome causes only mild unconjugated hyperbilirubinemia and does not cause kernicterus.
• D. Rotor syndrome also causes conjugated hyperbilirubinemia due to impaired hepatic storage and excretion, unrelated to UGT1A1 deficiency.

Anion gap is calculated as Na+ - (Cl- + HCO3-) = 138 - (96 + 8) = 34 mEq/L, which is markedly elevated above the normal range of 8-16 mEq/L. This confirms a high anion gap metabolic acidosis, consistent with diabetic ketoacidosis, where accumulation of beta-hydroxybutyrate and acetoacetate anions widens the gap. The low HCO3- and compensatory tachypnea (Kussmaul breathing) support this diagnosis. Other causes of high anion gap acidosis include lactic acidosis, uremia, and toxic alcohol ingestion (the mnemonic MUDPILES).

• A. Incorrect arithmetic; this value would suggest a normal anion gap acidosis, which does not fit this clinical picture.
• B. Incorrect arithmetic; this overestimates the gap.
• D. Incorrect arithmetic; this underestimates the true gap.

Proximal (type II) RTA results from a defect in proximal tubular bicarbonate reabsorption, leading to bicarbonate wasting along with other proximal tubular functions such as glucose, amino acid, and phosphate reabsorption, producing a Fanconi-like picture. Because distal acidification remains intact, the urine can still be acidified to a pH below 5.5 once serum bicarbonate falls below the reduced renal threshold, as seen here with urine pH 5.2. In contrast, distal (type I) RTA shows an inability to acidify urine despite systemic acidosis, with urine pH persistently above 5.5. The presence of generalized proximal tubular dysfunction (glucosuria, aminoaciduria, phosphaturia) points specifically to type II RTA.

• A. This describes type IV RTA, which is associated with hyperkalemia, not the hypokalemia seen in this case.
• B. This is a feature of type IV RTA related to aldosterone deficiency or resistance, not proximal RTA.
• D. This describes distal (type I) RTA, which is inconsistent with the urine pH of 5.2 and the proximal tubular wasting pattern seen here.

SIADH is characterized by euvolemic hyponatremia with inappropriately concentrated urine (urine osmolality greater than 100 mOsm/kg) relative to low serum osmolality, along with urine sodium typically above 40 mEq/L, in the absence of renal, adrenal, or thyroid dysfunction or diuretic use. Small cell lung carcinoma is a classic paraneoplastic cause due to ectopic ADH secretion, which causes water retention and dilutional hyponatremia without volume overload. The combination of low serum osmolality with an inappropriately high urine osmolality confirms failure to suppress ADH despite hypotonicity. Cerebral salt wasting is excluded because that condition causes hypovolemia with renal sodium loss, not euvolemia.

• A. Primary polydipsia typically causes dilute urine (low urine osmolality), not concentrated urine as seen here.
• B. Cerebral salt wasting causes hypovolemia with volume depletion, unlike the euvolemic state described here.
• C. This patient is euvolemic, not hypovolemic, and is not on diuretics.

In chronic kidney disease, the primary mechanism of hyperkalemia is decreased glomerular filtration rate leading to impaired renal excretion of potassium, since the kidney is the main route of potassium elimination. As GFR falls below approximately 10-15 mL/min/1.73m2, the kidneys can no longer adequately excrete the daily potassium load, especially when dialysis sessions are missed. The characteristic ECG changes of hyperkalemia progress from peaked T waves to widened QRS, flattened or absent P waves, and eventually a sine-wave pattern as potassium rises. Aldosterone levels are typically appropriately elevated as a compensatory response in CKD, not the primary cause of hyperkalemia.

• B. Aldosterone would be expected to rise as a compensatory response to hyperkalemia and would promote potassium excretion, not retention; primary hyperaldosteronism causes hypokalemia.
• C. Insulin deficiency is a recognized cause of hyperkalemia but is not the primary mechanism in this patient with CKD and missed dialysis.
• D. Dietary excess alone rarely causes severe hyperkalemia in a person with normal renal function; here the primary defect is reduced excretory capacity.

Primary hyperparathyroidism, most commonly caused by a solitary parathyroid adenoma, presents with inappropriately elevated or high-normal intact PTH in the setting of hypercalcemia, along with hypophosphatemia due to PTH-mediated phosphate wasting in the proximal tubule. PTH increases bone resorption and renal calcium reabsorption while promoting urinary calcium excretion overall because the filtered load is increased, so urinary calcium is typically elevated rather than low. Mild elevation of alkaline phosphatase reflects increased osteoblastic activity secondary to PTH-driven bone turnover. This classic combination of high calcium, low phosphate, high PTH, and hypercalciuria distinguishes primary hyperparathyroidism from other causes of hypercalcemia.

• A. Vitamin D toxicity causes hypercalcemia with suppressed PTH and typically elevated serum phosphate, not hypophosphatemia.
• C. Familial hypocalciuric hypercalcemia presents with low urinary calcium excretion and only mildly elevated or normal PTH, unlike the elevated urinary calcium seen here.
• D. In malignancy-associated hypercalcemia from PTHrP, intact PTH levels are suppressed, not elevated, because PTHrP does not cross-react in the standard intact PTH assay.

Glucagon binds a Gs-coupled receptor that activates adenylyl cyclase, raising intracellular cAMP, which activates protein kinase A to stimulate glycogenolysis and gluconeogenesis in the liver. Angiotensin II acts through the Gq-coupled AT1 receptor, activating phospholipase C, which hydrolyzes PIP2 into IP3 and diacylglycerol, releasing intracellular calcium and activating protein kinase C. This distinction is a classic example of how different G-protein subtypes couple receptors to distinct second messenger cascades. Insulin, in contrast, works through a receptor tyrosine kinase mechanism, not a G-protein coupled pathway.

• A. This reverses the correct hormone-pathway pairing for Hormone A and Hormone B.
• C. Insulin does not signal through the IP3/DAG pathway; it uses receptor tyrosine kinase signaling.
• D. Insulin does not act through a Gs-coupled cAMP pathway; it signals via receptor tyrosine kinase.

Glucocorticoids, being lipophilic steroid hormones, diffuse freely across the plasma membrane and bind to cytoplasmic or nuclear glucocorticoid receptors. The hormone-receptor complex undergoes a conformational change, dissociates from heat shock proteins, dimerizes, and translocates to the nucleus where it binds glucocorticoid response elements on DNA. This binding modulates the transcription of target genes, upregulating anti-inflammatory proteins such as lipocortin-1 and downregulating pro-inflammatory cytokines. This genomic mechanism explains the characteristic delayed onset but prolonged duration of action of steroid hormones compared to peptide hormones acting through membrane receptors.

• A. This describes peptide hormone signaling (e.g., glucagon), not the mechanism of lipophilic steroid hormones.
• B. This describes growth factor or insulin signaling through receptor tyrosine kinases, not steroid hormone action.
• D. This describes neurotransmitter action at ligand-gated ion channels, not the genomic mechanism of steroid hormones.

Insulin binds the alpha subunits of its receptor, a receptor tyrosine kinase, causing autophosphorylation of the beta subunits and activation of intrinsic tyrosine kinase activity. This phosphorylates insulin receptor substrate (IRS) proteins, which recruit and activate PI3-kinase, generating PIP3 and activating Akt (protein kinase B). Activated Akt triggers translocation of GLUT4-containing vesicles from intracellular storage sites to the plasma membrane, increasing glucose uptake in skeletal muscle and adipose tissue within minutes. This rapid, non-genomic mechanism is distinct from the slower transcriptional effects insulin also has on metabolic enzyme gene expression.

• A. Insulin receptor signaling does not involve adenylyl cyclase or cAMP; GLUT4 translocation is driven by the PI3-kinase/Akt pathway.
• C. Insulin does not signal through a G-protein coupled receptor or phospholipase C pathway; this describes a different class of hormone receptor.
• D. Insulin acts through a cell surface receptor tyrosine kinase, not an intracellular cytoplasmic receptor like steroid hormones.

Polymerase chain reaction (PCR) relies on a heat-stable DNA polymerase, classically Taq polymerase from Thermus aquaticus, to extend primers at high temperatures (around 72°C) across repeated thermal cycles without denaturing. This enzyme tolerates the 94-95°C denaturation step repeated for 25-35 cycles, allowing exponential doubling of the target DNA sequence each cycle. This principle underlies CBNAAT/Xpert MTB-RIF, which also uses real-time PCR to detect rpoB gene mutations for rifampicin resistance. Reverse transcriptase is used in RT-PCR to convert RNA to cDNA first, not in standard DNA amplification.

• A. RNA polymerase II transcribes DNA into mRNA in eukaryotic cells and plays no role in PCR.
• B. Reverse transcriptase converts RNA to DNA and is used only when the starting template is RNA (RT-PCR), not for amplifying existing DNA.
• D. DNA ligase joins DNA fragments by forming phosphodiester bonds and is used in cloning, not in PCR amplification.

NACO's HIV testing strategy for diagnosis requires a sample reactive on the first ELISA/rapid test to be retested with two additional assays based on different antigens or test principles, following the three-test strategy for diagnosis. A sample is labelled HIV-positive only when it is reactive on all three different assays. Western blot, though historically used as confirmatory in some countries, is not part of the standard NACO algorithm due to high cost and limited availability. Viral load and CD4 count are used for monitoring and staging, not for establishing initial diagnosis.

• B. CD4 count assesses immune status for staging and treatment initiation, not for confirming HIV infection.
• C. Western blot is not part of the NACO three-test diagnostic strategy in India; it is costly and not used for routine confirmation here.
• D. Viral load testing is used for monitoring disease progression and treatment response, not for initial diagnostic confirmation.

Northern blot is used to detect and analyze RNA, particularly mRNA, making it the appropriate technique for studying gene expression at the transcript level. The sample RNA is separated by electrophoresis, transferred to a membrane, and hybridized with a labelled complementary probe. Southern blot detects DNA fragments (used in genetic mutation analysis, paternity testing), while Western blot detects proteins using antibodies. Southwestern blot is a specialized technique detecting DNA-binding proteins, not mRNA.

• A. Southern blot is used to detect and analyze DNA fragments, such as in restriction fragment length polymorphism analysis, not RNA.
• C. Western blot detects proteins using specific antibodies, not RNA transcripts.
• D. Southwestern blot identifies DNA-binding proteins, not mRNA expression levels.

Huntington disease is an autosomal dominant trinucleotide (CAG) repeat disorder showing genetic anticipation, where repeat length tends to expand further during spermatogenesis due to instability of the repeat sequence during DNA replication. Larger repeat numbers correlate with earlier age of onset and greater disease severity in subsequent generations, especially with paternal transmission. The CAG repeat codes for glutamine, and expanded repeats produce a toxic mutant huntingtin protein with expanded polyglutamine tracts. This mechanism of anticipation is also seen in myotonic dystrophy and fragile X syndrome.

• A. Huntington disease is not an imprinted disorder; the anticipation effect is linked to CAG repeat instability, not allele silencing.
• B. Huntington disease is a nuclear gene disorder, not a mitochondrial disorder; heteroplasmy is irrelevant here.
• D. Anticipation in Huntington disease results from a specific, predictable mechanism (repeat instability), not random independent somatic mutation.

The pattern described, affected mother transmitting disease to all her children (both sons and daughters) while an affected father transmits to none of his children, is characteristic of mitochondrial inheritance. This occurs because mitochondria and their DNA are inherited almost exclusively from the ovum cytoplasm, not sperm. Ragged red fibers on muscle biopsy are a classic histological finding in mitochondrial myopathies due to the accumulation of abnormal mitochondria beneath the sarcolemma. Conditions like mitochondrial encephalomyopathy and chronic progressive external ophthalmoplegia follow this maternal transmission pattern.

• B. X-linked recessive disease typically affects males whose mothers are carriers, not daughters, and is transmitted via maternal carriers, not matching this family pattern directly here.
• C. Autosomal recessive inheritance requires two carrier parents and is unrelated to the strict maternal line transmission seen in this family.
• D. Autosomal dominant inheritance would show transmission from either affected parent to roughly half of offspring of both sexes; here only the mother transmits the disease.

Kwashiorkor results from severe dietary protein deficiency despite relatively adequate caloric (carbohydrate) intake, leading to hypoalbuminemia, which reduces plasma oncotic pressure and causes generalized edema. The characteristic features, edema, flaky-paint dermatosis, hair changes, hepatomegaly and preserved subcutaneous fat, distinguish it from marasmus. Marasmus, in contrast, results from combined protein-calorie deficiency with severe wasting of fat and muscle but without edema, as albumin levels are usually relatively preserved. The retained subcutaneous fat and low albumin in this child point specifically to protein deficiency as the predominant defect.

• A. Fat deficiency is not the primary defect in kwashiorkor; the hallmark is protein deficiency causing hypoalbuminemia.
• B. Pure caloric deficiency describes marasmus, which presents with severe wasting and loss of subcutaneous fat, not edema with preserved fat as seen here.
• D. Edema in kwashiorkor is due to hypoalbuminemia, not excess carbohydrate causing osmotic retention.

CA 19-9 is the most useful and widely used tumor marker for pancreatic adenocarcinoma, both for supporting diagnosis in the appropriate clinical context and for monitoring response to treatment and detecting recurrence. It is a sialylated Lewis blood group antigen found elevated in over 70-80% of pancreatic cancer cases, though it lacks specificity and can be elevated in biliary obstruction and other malignancies. CEA is more commonly associated with colorectal carcinoma, AFP with hepatocellular carcinoma and germ cell tumors, and PSA with prostate carcinoma. The clinical picture here, painless jaundice with a palpable gallbladder (Courvoisier sign) and a pancreatic head mass, is classic for pancreatic cancer.

• B. CEA is primarily associated with colorectal carcinoma and is less specific or sensitive than CA 19-9 for pancreatic cancer.
• C. AFP is the marker for hepatocellular carcinoma and germ cell tumors, not pancreatic adenocarcinoma.
• D. PSA is specific to prostate carcinoma and is irrelevant to this clinical presentation.